PANACEABIO· Health Care› Biotechnology

Panacea Biotec Ltd

Stage 4 · Declining · week 8

As of 20 Nov 2026, Panacea Biotec is in Stage 4, the downtrend phase, now in week 8 (since 29 Sep 2026). It closed at ₹336, 44.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition produ… More about the company

₹336
Close, 20 Nov 2026
-4.79% on the day
₹2,053 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dBiotechnology 33.3%0.0 pts

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

RS rank

Edge

—

PANACEABIO is in a decline, 15% below its 200-day average. Declining stocks have lagged the market more than any other group; we wait for a base before looking again.

Its relative strength is 45 of 99, below the middle among NSE stocks over the past year. Biotechnology ranks 11 of 106 industries by the strength of its stocks, among the leaders.

Is PANACEABIO early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 26w
S4 19w
S2 23w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 26w → S3 5w → S4 19w → S1 2w → S2 23w → S3 8w → S2 12w → S3 6w → S4 9w → S1 5w → S4 13w → S1 1w → S4 10w → S1 4w → S2 10w → S3 6w → S4 8w current
Total tracked: 168 weeks across 17 stage runs.

PANACEABIO among Biotechnology8th of 9 by relative strength

All 9 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1ACUTAASStage 2 · wk 396+21.6%
2SAILIFEStage 2 · wk 3796+29.2%
3ANTHEMStage 3 · wk 286+18.1%
4HESTERBIOStage 3 · wk 786+7.4%
53BBLACKBIOStage 2 · wk 761−1.0%
6ONESOURCEStage 1 · wk 158+18.6%
7BIOCONStage 4 · wk 550+8.8%
8PANACEABIOStage 4 · wk 845−1.0%
vs 52W High
-44.7%
₹296.1 lo₹607.8 hi
44.7% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 8
1w13w26w
Week 8, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-15.4%
200 DMA: ₹397.1 · sloping down
The stock is below its 200-day average, the mark of a downtrend. Stage analysis waits for the price to reclaim that line.
Rel Volume
1.66x
vs 50-day avg
Volume ran well above average on a down day. In Stage 4 that points to continued institutional selling.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-1.0%
3M
-16.6%
6M
-19.7%
YTD
-10.7%
1Y
-17.0%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Biotechnology
→ Flat
Stage 2%
33.3%
20d Δ
+0.0pp
1M return
+17.1%
3M return
+4.9%
Industry Stage-2 % · last 20 days
Industry has 3 Stage 2 leaders. See Biotechnology Stage 2 →

Mutual fund holdings

Held by 1 mutual funds in portfolios to October 2026: 0 active funds and 1 index funds and ETFs.

In October, no active fund changed its holding.

All 1 funds and what each did in October

Mutual funds holding PANACEABIO: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 9 Jun 2026
Recent Stage Timeline
2026-11-20S4
Wk 8 · Vol 1.66x
2026-11-19S4
Wk 7 · Vol 0.63x
2026-11-18S4
Wk 7 · Vol 1.58x
2026-11-17S4
Wk 7 · Vol 0.94x
2026-11-16S4
Wk 7 · Vol 6.61x
2026-11-13S4
Wk 7 · Vol 0.61x
2026-11-12S4
Wk 6 · Vol 0.56x
2026-11-11S4
Wk 6 · Vol 0.45x
2026-11-09S4
Wk 6 · Vol 1.11x
2026-11-06S4
Wk 6 · Vol 0.41x
2026-11-05S4
Wk 6 · Vol 0.87x
2026-11-04S4
Wk 5 · Vol 0.80x
Moving averages & range
50 DMA
₹355
200 DMA
₹397.1
52W High
₹607.8
52W Low
₹296.1
5D Low
₹336
Resistance levels (recent highs)
20d High
₹361.5
60d High
₹405.9
120d High
₹607.8
250d High
₹607.8
Next resistance
+7.6%
to 20d High
Earnings Growth (YoY)
-42.4%
Revenue +19.7%
Dividend Yield
0.00%
P/B 2.8

Panacea Biotec: quick answers

What stage is Panacea Biotec in?

As of 20 Nov 2026, Panacea Biotec (PANACEABIO) is in Stage 4, the downtrend phase. It entered Stage 4 on 29 Sep 2026 and is in week 8. What the four stages mean

Is Panacea Biotec in an uptrend?

No. Panacea Biotec is in a Stage 4 downtrend. It trades 15.4% below its 200-day average, which is falling.

How far is Panacea Biotec from its 52-week high?

Panacea Biotec closed at ₹336 on 20 Nov 2026, 44.7% below its 52-week high of ₹608. Its 52-week low is ₹296.

How has Panacea Biotec performed over the past year?

As of 20 Nov 2026, Panacea Biotec is down 17.0% over the past year and down 10.7% so far in 2026.

Which sector and industry is Panacea Biotec in?

Panacea Biotec is in the Biotechnology industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care

About this companyHealth Care· Biotechnology

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.